Quality Systems – Page 265

Endotoxin Oos during campaign changeover: FDA/MHRA investigation narrative and batch impact

Investigating Endotoxin OOS Results During Campaign Changeovers in Pharma Manufacturing Endotoxin contamination can significantly disrupt parenteral manufacturing, particularly during campaign changeovers where different products are processed sequentially in the same…

Odor Change after excipient change: GMP investigation and CAPA strategy

GMP Investigation into Odor Change Following Excipient Modification In pharmaceutical manufacturing, the integrity of formulations is paramount, and even minor changes can yield significant sensory impacts. One such issue arises…

Bioburden Spike Pre-Filtration during routine EM trending: risk assessment for patient safety and recall

Addressing Bioburden Spikes Pre-Filtration during Routine Environmental Monitoring: A Comprehensive Investigation In modern pharmaceutical manufacturing, especially concerning parenteral dosage forms, bioburden control is paramount. A recent signal indicating unexpected spikes…

Particulate Matter Oos during hold-time study: how to classify deviation and set disposition

Classifying Deviations from OOS Results of Particulate Matter During Hold-Time Studies In the realm of pharmaceutical manufacturing, maintaining compliance with stringent regulatory standards is paramount. An unexpected Out-of-Specification (OOS) result…

Tube Leakage Complaint in cream manufacturing: complaint trending and risk-based actions

Investigating Tube Leakage Complaints in Cream Manufacturing: Trending and Risk Mitigation Strategies In the realm of pharmaceutical manufacturing, particularly in topical dosage forms such as creams, tube leakage complaints can…

Filter Integrity Failure during power interruption: facility, people, process root cause mapping

Understanding Filter Integrity Failure During Power Interruptions: A Comprehensive Root Cause Investigation Filter integrity failures during power interruptions can lead to significant deviations and contamination risks in pharmaceutical manufacturing, particularly…

Bioburden Spike Pre-Filtration during routine EM trending: data integrity checks for lab and shop floor

Addressing Bioburden Spikes Before Filtration: Ensuring Data Integrity in Environmental Monitoring Trending In pharmaceutical manufacturing, particularly within sterile environments, bioburden control is paramount. Bioburden spikes detected during routine environmental monitoring…

Color Change during method transfer: cleaning validation and worst-case selection

Investigating Color Change during Method Transfer in Pharmaceutical Manufacturing Color change during method transfer processes can present significant challenges in pharmaceutical manufacturing, particularly regarding cleaning validation and worst-case scenario selection.…

Em Excursion In Grade A during hold-time study: facility, people, process root cause mapping

Identifying Root Causes of Em Excursion in Grade A during Hold-Time Studies In pharmaceutical manufacturing, maintaining controlled environments is critical to ensuring product quality, especially in the production of parenteral…

Sterility Test Failure post-sterile filtration: risk assessment for patient safety and recall

Assessing Risk and Investigating Sterility Test Failures After Sterile Filtration Sterility test failures following sterile filtration represent a significant concern within pharmaceutical manufacturing, particularly for parenteral dosage forms. Such events…

Cleaning Validation Failure during method transfer: mixing and sampling controls for QA review

Investigating Cleaning Validation Failures During Method Transfer: Key Controls and CAPA Insights In pharmaceutical manufacturing, especially in topical and dermatological dosage forms, maintaining rigorous cleaning validation protocols is critical. A…

Bioburden Spike Pre-Filtration during power interruption: facility, people, process root cause mapping

Investigating Bioburden Spikes Pre-Filtration During Power Interruptions in Pharmaceutical Manufacturing Bioburden spikes in pharmaceutical manufacturing, particularly during the pre-filtration stage, can pose significant risks to product quality and regulatory compliance.…